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Although recipients of a first HLA-identical living-donor kidney transplant seem to need less immunosuppression,
there are no guideline recommendations for these patients, and few prospective trials are available.
Methods: We analyzed all PRA-negative patients who received a first kidney transplant from an HLA-identical living donor.
The patients received no antibody induction. An intraoperative bolus of 500 mg of methylprednisolone was administered.
Then, steroid therapy was withdrawn within one week. Tacrolimus and mycophenolate treatment were started 3 days
before transplantation with tacrolimus target levels of 4 to 8 ng/mL. In the absence of rejection, tacrolimus was withdrawn
between 3 and 12 months post-transplant to reach mycophenolate mofetil monotherapy of 2 g/day or equivalent.
Results: Six patients were treated with the above protocol. At last follow-up, graft and patient survival were 100%. MDRD
glomerular filtration rates were 54, 60, and 62 mL/min at 3 months, 12 months and last follow-up, respectively. None of
the patients developed PRA post-transplant. One episode of acute rejection Banff IA occurred 9 years after transplant-
ation due to non-adherence with good outcome after treatment. The mean number of
concomitant drugs given with mycophenolate was 2.6. Four patients needed antihypertensive drugs.
Conclusion: Steroid-free de novo treatment and calcineurin-inhibitor weaning with mycophenolate monotherapy
is feasible in first HLA-identical kidney transplantation from a living sibling.Introduction
Only a very small group of patients receive kidney trans-
plants from an HLA-identical sibling. However, these
patients show excellent long-term graft outcome and seem
to need significantly less immunosuppression compared
with recipients from nonHLA-identical donor kidneys
[1-5]. In general, withdrawal or minimization of immuno-
suppressive treatment has been one of the objectives in
low immunological risk patients [6,7]. However, since only
a minority of kidney transplants is performed among
HLA-identical siblings, few studies have been carried out
in these patients, and ‘how much is less’ remains poorly
defined. No clear recommendation is given in the KDIGO* Correspondence: fdiekman@clinic.ub.es
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stated.guidelines for immunosuppression in kidney transplant-
ation from a living HLA-identical donor [8].
The aim of this report is to increase the data available
on HLA identical kidney transplantation in order to avoid
unnecessary and potentially dangerous over-immunosup-
pression in these patients.
We describe our experience of 10 years of HLA-identical
living donor kidney transplantation without induction
treatment, a 7-day course of steroid treatment, calcineurin
inhibitor withdrawal during the first year and mycopheno-
late monotherapy as maintenance treatment.
Patients and methods
We report retrospectively on all consecutive PRA-negative
patients from our center who received a first kidney trans-
plant from an HLA-identical living donor between January
2003 and December 2010. This retrospective analysis was
approve by the Review Board of Clinical Investigationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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clusion criteria were HLA identity, living donor transplant,
first transplant, and absence of HLA antibodies as tested
with Luminex™ HLA antibody test class I and II (One-
Lambda, Canoga Park, California, USA). Exclusion criteria
were repeat transplant, double transplant, and Luminex™
class I or II positivity. The patients received no antibody
induction and an intraoperative methylprednisolone bolus
of 500 mg. On postoperative day 1 (POD1), they received
125 mg of methylprednisolone intravenously (i.v.), and on
POD2 the patients were given 0.5 mg/kg of methylprednis-
olone. Then, the patients continued with oral prednisone
until abrupt withdrawal after POD6. Tacrolimus (target
levels of 4 to 8 ng/mL) and mycophenolate treatment
(500 mg twice per day (BID) pre-transplant and 1 g BID
post-transplant or equivalent) were started 3 days before
transplantation. Post-transplant tacrolimus concentrations
were kept between 4 and 8 ng/mL. In the year 2009 our
unit started a protocol biopsy program with biopsies at
3 and at 12 months for all kidney transplant recipients,
including patients who received a transplant from an
HLA-identical sibling from 2009 onwards. In the absence
of clinical (and histopathological) signs of rejection, tacro-
limus was slowly withdrawn between 3 and 12 months
post-transplant to reach mycophenolate monotherapy of
1 g BID of CellCept™ or 720 mg BID of Myfortic™.
Valganciclovir was given as CMV prophylaxis in all
donor positive/recipient negative patients until POD 90.
Otherwise, pre-emptive therapy was performed. All patients
received sulfamethoxazole/trimethoprim prophylaxis for
6 months.
Routine follow-up was performed with weekly visits in
the outpatient department until POD30, then every 2
weeks until POD90 and monthly visits thereafter until 1
year. After 1 year, follow-up was performed every 3 months.
Graft function was evaluated according to the Modification
of Diet in Renal Disease equation (MDRD). Body weight
and blood pressure were recorded, and routine blood tests
were performed according to our center protocol.
Statistical analysis
Values are described as mean, standard deviation and
range. The Wilcoxon test was performed in order to
detect statistically significant differences. All P values
were obtained as two sided and were considered to be
significant if <0.05.
Results
Six PRA-negative first kidney transplant recipients who
received a kidney from an HLA-identical living donor
between 1 January 2003 and 31 December 2010 were
identified (Table 1). They had a mean follow-up of 73.3 ±
36 months (33 to 121). Mean recipient age at transplant-
ation was 49 ± 3 years; mean donor age was 48.7 ± 3 years.Causes of end-stage renal disease included IgA nephropa-
thy (n = 2), hypertensive nephropathy (n = 3), and vesicour-
eteral reflux (n = 1). All but one patient were transplanted
pre-emptively. One patient had been on hemodialysis for
54 months prior to transplantation. No patient showed
pre-transplant anti-HLA antibodies, and no HLA antibodies
were detected after transplantation by Luminex technology.
Patient and graft survival was 100% at 1 year and at
last follow-up.
Mean serum creatinine was 1.45 ± 0.19 mg/dL at 3
months, 1.32 ± 0.16 mg/dL at 1 year, and 1.26 ± 0.10 mg/dL
at last follow-up corresponding to a glomerular filtration
rate (MDRD) of 54 ± 9.3, 60 ± 8.1 and 62 ± 8.4 mL/min,
respectively. The difference in kidney function between
3 months and last follow-up was statistically significant
(P = 0.042 for creatinine and 0.043 for MDRD). Median
proteinuria was 194 mg/day (Quartile 1 (Q1): 129; Quar-
tile 3 (Q3): 268; interquartile range (IQR): 139) at 3
months and 280 mg/day (Q1: 155; Q3: 397; IQR: 242) at 1
year. Mean blood pressure at 1 year was 131/80 mmHg.
Four patients were on antihypertensive drugs at last
follow-up.
One patient with unknown native kidney disease devel-
oped late acute rejection Banff IA at 9 years post-trans-
plantation after taking mycophenolate on an irregular basis
during the preceding months. This patient showed an
increase of serum creatinine from 1.2 mg/dL to 1.4 mg/dL
at the time of rejection and an increase of proteinuria and
was treated with a bolus of 250 mg methylprednisolone
each on three consecutive days and subsequent steroid
tapering during the following 2 weeks and returned to
his baseline graft function and proteinuria at last follow-
up. No antibodies were detected in the Luminex™ screen-
ing at time of rejection or afterwards.
No unplanned rehospitalizations were necessary after
transplantation in any of the patients. No major abnor-
malities of the hemogram or lipid profiles occurred.
One patient had a history of pre-transplant diabetes
and remained on oral antidiabetics after transplantation.
Discussion
We observed excellent outcomes in first HLA-identical
living-donor kidney transplant recipients on mycophe-
nolate monotherapy.
Living donor kidney transplantation from HLA-identical
siblings only accounts for approximately five percent of
all living-donor renal transplants in the United States.
The percentage is even lower taking into account all
renal transplants performed including transplants from
cadaveric donors [9]. On the other hand transplants from
HLA-identical siblings achieve excellent long-term out-
comes compared with HLA-mismatched living-donor
renal transplants [10,11]. According to the UNOS data-
base these transplants achieve 5-year graft and patient
Table 1 Patient characteristics and clinical outcome
Recipient 1 Recipient 2 Recipient 3 Recipient 4 R cipient 5 Recipient 6
Recipient age (yr) 40 33 62 64 5 45
Recipient sex Female Male Male Male M le Male
Initial disease Hypertensive
nephropathy
IgA Nephropathy IgA Nephropathy Hypertensive nephropathy H pertensive nephropathy Vesicoureteral
reflux + left
kidney atrophy
Dialysis (months) 0 0 54 0 0 0
Donor age (yr) 44 39 61 50 4 49
PRA 0 0 0 0 0 0
Renal biopsy 3 mo Not performed Not performed Not performed Not performed N rmal Normal
SCr at 3 mo (mg/dl) 1.4 mg/dL 1.5 mg/dL 1.7 mg/dL 1.2 mg/dL 1 mg/dL 1.3 mg/dL
eGFR (mL/min/1.73 m2) 44 57 44 65 4 63
Biopsy at 1 year Not performed Not performed Not performed Not performed N rmal Normal
SCr at 1 yr 1.2 mg/dl 1.4 mg/dl 1.6 mg/dl 1.2 mg/dl 1 mg/dl 1.2 mg/dl
eGFR (mL/min/1.73 m2) 53 62 47 65 6 69
Follow-up (mo) 121 98 96 54 3 33
Renal function at
last follow-up:
SCr at last follow-up
(mg/dL)
1.3 mg/dl 1.3 mg/dl 1.2 mg/dl 1.1 mg/dl 1 mg/dl 1.3 mg/dl
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the possible reasons for this might be the fact that acute
rejection rates in transplantation from HLA-identical
siblings are significantly lower than in transplant recipients
from nonHLA-identical donors [13]. However, as can
be seen from one of our patients, a minimal amount of
immunosuppression still remains necessary even years
after HLA-identical transplantation. This patient devel-
oped mild cellular rejection due to non-adherence.
In most centers, more than 85% of kidney graft recipi-
ents receive a long-term therapy containing a calcineurin
inhibitor [14]. On the other hand long-term calcineurin
inhibitor therapy is associated with severe side effects such
as cardiovascular disease and cancer. Since only a small
percentage of recipients of living-donor kidneys receive
transplants from HLA-identical siblings there are no sys-
tematic randomized controlled trials available.
Walker and colleagues published a study on 20 HLA-
identical living-donor kidney transplants who were treated
without steroids and with low-dose calcineurin-inhibitors
and the mTOR inhibitor, rapamycin. Tacrolimus was with-
drawn at month 3 and SRL at 1 year, and the patients were
left on mycophenolate monotherapy after 1 year, which
was considered to be safe with a follow-up period of 18
months [15]. Venot and colleagues report on seven HLA-
identical living-donor transplant recipients who received
polyclonal antibody induction and mycophenolate (six
cases) or rapamycin (one case) monotherapy, and achieved
excellent results [16]. Leventhal and colleagues recently
published the results of a tolerance induction trial in
transplant recipients from HLA identical siblings. The
patients were treated with alemtuzumab, donor hema-
topoietic stem cells, tacrolimus and mycophenolate, and
later were converted to sirolimus. Finally, complete drug
withdrawal was performed at 24 months. Five out of ten
patients with at least 36 months of follow-up had the
immunosuppression successfully withdrawn, two had
disease recurrence and three subclinical rejections [17].
Van der Wetering and colleagues chose 29 out of 83
kidney transplant recipients from an HLA-identical donor
and converted them from a dual therapy consisting of
steroids in combination with either azathioprine or my-
cophenolate to steroid monotherapy [18]. One patient
developed JC-virus nephropathy with subsequent graft loss,
and one patient refused further reduction of immuno-
suppression. In their cohort four patients on steroid
monotherapy developed recurrence of the original disease,
however, only one of these patients showed a transient
decline of graft function. The observation period was
24 months. Bartucci and colleagues converted 11 HLA-
identical kidney transplant recipients successfully from
CNI-based treatment to azathioprine monotherapy with-
out deterioration of kidney function in the observation
period of 76 months; however, they state that the possiblebenefits must be carefully balanced against an associated
risk of acute rejection [19].
Our data contributes to those reported in the literature
and might help define a potential group of recipients of
kidney grafts from HLA-identical siblings, who could
be on long-term mycophenolate monotherapy, that is,
recipients of a first kidney transplant without anti-HLA
antibodies (negative PRA testing by cytotoxicity and
negative Luminex™ testing).
Conclusion
A stepwise reduction of immunosuppression to reach
mycophenolate monotherapy might be a practical and
reasonably safe method that could offer a sufficient level
of immunosuppression to those patients receiving a first
HLA-identical kidney transplantation from a living sibling
without unnecessary exposure to expensive and potentially
harmful treatments.
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